Prices are updated after-hours

Health Technology 425

Timber Pharmaceuticals, Inc.

TMBR | $0.3426 -2.69% 3K

(0.0% 1d) (0.0% 1m) (-75.9% 1y) (0.0% 2d) (0.0% 3d) (1.4% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 1,176,055
http://www.timberpharma.com/
Sec Filling | Patents | 3 employees

(US) Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, tuberous sclerosis complex and localized scleroderma. The company is headquartered in Woodcliff Lake, NJ.

sclerosis msa treatment

add to watch list Paper trade email alert is off

Acer Therapeutics Inc.

ACER | $0.9 -3.61% 420K

Health Technology

(0.0% 1d) (0.0% 1m) (3.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1077.06% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 22,017,353
http://www.acertx.com
Sec Filling | Patents | 17 employees

(US) Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.

acquisitions urine urea treatment

add to watch list Paper trade email alert is off

Diffusion Pharmaceuticals Inc.

DFFN 4 | $6.6 11.68% -34.32% 350K

Health Technology

(0.0% 1d) (0.0% 1m) (15.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (308.49% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 13,465,894
http://www.diffusionpharma.com
Sec Filling | Patents | 10 employees

(US) Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

treatment

add to watch list Paper trade email alert is off

Amryt Pharma plc

AMYT | News | $14.7 0.0% 2.4M

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 940,255,350
http://amrytpharma.com
Sec Filling | Patents | n/a employees

Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. It operates through the following segments: Commercial, Research and Development. The Commercial segment includes the financial results of the Group's two current commercial product lines, Imlan and Lojuxta. The Research and Development segment comprises the financial results of the Group’s two current research and development assets, AP101 and AP102. The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.

treatment

Drugs

Juxtapid (lomitapide mesylate)
Myalept (metreleptin)

add to watch list Paper trade email alert is off

Applied Molecular Transport Inc.

AMTI 4 | $0.263 -14.3% -1.14% 0

Health Technology

(0.0% 1d) (0.0% 1m) (-2.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (10.46% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 10,871,516
http://www.appliedmt.com
Sec Filling | Patents | 80 employees

Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.

autoimmunity metabolic treatment

add to watch list Paper trade email alert is off

Chinook Therapeutics, Inc.

KDNY | $40.39 0.22% -0.17% 0

Health Technology

(0.0% 1d) (0.0% 1m) (83.6% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (-30.62% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,900,203,021
http://www.chinooktx.com
Sec Filling | Patents | 96 employees

(US) Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

kidney diseases kidney

add to watch list Paper trade email alert is off

Ayala Pharmaceuticals, Inc.

AYLA | $0.5036 5.84% -0.7% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (15.3% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 7,463,718
http://www.ayalapharma.com
Sec Filling | Patents | 29 employees

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel.

cancer israel diagnostics

add to watch list Paper trade email alert is off

Metacrine, Inc.

MTCR | $0.5814 -5.14% 84K

Health Technology

(0.0% 1d) (0.0% 1m) (3.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-50.69% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 24,749,916
http://www.metacrine.com
Sec Filling | Patents | 35 employees

Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.

gastrointestinal liver

add to watch list Paper trade email alert is off

Infinity Pharmaceuticals, Inc.

INFI | $0.016 12.5% 1.1M

Health Technology

(0.0% 1d) (0.0% 1m) (-90.3% 1y) (-4.8% 2d) (28.0% 3d) (0.0% 7d) (264.12% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 1,452,177
http://www.infi.com
Sec Filling | Patents | 25 employees

(US) Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

cancer msa

add to watch list Paper trade email alert is off

NuVasive, Inc.

NUVA | $39.75 -2.24% -2.29% 0

Health Technology

(0.0% 1d) (0.0% 1m) (-6.8% 1y) (0.0% 2d) (-2.2% 3d) (0.0% 7d) (156.26% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,084,854,388
http://www.nuvasive.com
Sec Filling | Patents | 2800 employees

(US) NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

add to watch list Paper trade email alert is off

Surface Oncology, Inc.

SURF | $1.07 -0.93% -1.41% 0

Health Technology

(0.0% 1d) (0.0% 1m) (67.2% 1y) (0.0% 2d) (-0.9% 3d) (0.0% 7d) (78.2% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 65,082,187
http://www.surfaceoncology.com
Sec Filling | Patents | 49 employees

(US) Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

cancer t-cell cd73 msa ceiling

add to watch list Paper trade email alert is off

TCR2 Therapeutics Inc.

TCRR 4 | $1.48 3.38% 3.9M

Health Technology

(0.0% 1d) (0.0% 1m) (-16.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (906.93% volume)
Earnings Calendar: 2023-08-07
Market Cap: $ 58,107,383
http://www.tcr2.com
Sec Filling | Patents | 83 employees

(US) TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. The firm offers cancer therapy, t-cell biology, immunology and molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of t-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.

cancer immunotherapy immunology t-cell ceiling

add to watch list Paper trade email alert is off

Tyme Technologies, Inc.

TYME | $0.3107 -8.21%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (8.1% 2d) (18.4% 3d) (0.0% 7d) (-9.91% volume)
Earnings Calendar:
Market Cap: $ 53,504,682
http://www.tymeinc.com
Sec Filling | Patents | 18 employees

(United States) Tyme Technologies, Inc. is a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.

cancer t-cell ceiling

add to watch list Paper trade email alert is off

SeaSpine Holdings Corporation

SPNE | $9.54 8.29% -1.99%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (314.37% volume)
Earnings Calendar: 2023-03-10
Market Cap: $ 354,914,712
http://www.seaspine.com
Sec Filling | Patents | 386 employees

(US) SeaSpine Holdings Corp. is a medical technology company, which engages in the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It products include thoracolumbar hardware, cervical hardware, orthobiologics, and spine pure strip. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA.

treatment

add to watch list Paper trade email alert is off

Ra Medical Systems, Inc.

RMED | $0.594 0.0% 78K

Health Technology

(0.0% 1d) (0.0% 1m) (-55.0% 1y) (0.0% 2d) (10.0% 3d) (0.0% 7d) (-40.66% volume)
Earnings Calendar:
Market Cap: $ 3,188,398
http://www.ramed.com
Sec Filling | Patents | 79 employees

(US) Ra Medical Systems, Inc. engages in the design, development, and commercialization of excimer lasers for the treatment of dermatologic and cardiovascular diseases. Its product, Pharos, is used for the treatment of difficult-to-treat, chronic diseases including psoriasis and vitiligo. It operates through the Dermatology and Vascular business segments. The company was founded by Dean Irwin and Melissa Burstein in 2002 and is headquartered in Carlsbad, CA.

cardiovascular treatment

add to watch list Paper trade email alert is off

F-star Therapeutics Inc.

FSTX | $7.12 0.0% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-03-14
Market Cap: $ 156,511,263
http://www.f-star.com
Sec Filling | Patents | 30 employees

(US) F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm’s product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company is headquartered in Cambridge, the United Kingdom.

cancer antibody

add to watch list Paper trade email alert is off

MedAvail Holdings Inc.

MDVL 4 | $1.8 -0.56% 250K

Health Technology

(0.0% 1d) (0.0% 1m) (597.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (187.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,905,040
https://medavail.com
Sec Filling | Patents | 15 employees

(US) MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.

optical

add to watch list Paper trade email alert is off

ADiTx Therapeutics, Inc.

ADTX | $2.27 2.84% 27K

Health Technology

(0.0% 1d) (-28.5% 1m) (226.8% 1y) (0.0% 2d) (2.3% 3d) (-5.8% 7d) (4.51% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 3,780,036
http://www.aditxt.com
Sec Filling | Patents | 2 employees

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

immunotherapy autoimmunity transplanted organs

add to watch list Paper trade email alert is off

Neurotrope, Inc.

NTRP | $2.86 -10.93% 610

Health Technology

(0.0% 1d) (-33.3% 1m) (-35.1% 1y) (0.0% 2d) (-2.4% 3d) (5.1% 7d) (34.07% volume)
Earnings Calendar:
Market Cap: $ 2,232,010
http://www.neurotropebioscience.com
Sec Filling | Patents | 7 employees

Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.

neurodegenerative alzheimer treatment alzheimer’s

add to watch list Paper trade email alert is off

Qualigen Therapeutics, Inc.

QLGN | $0.296 -6.03% -6.42% 24K

Health Technology

(0.0% 1d) (-16.9% 1m) (-64.0% 1y) (0.0% 2d) (6.7% 3d) (0.0% 7d) (-69.69% volume)
Earnings Calendar: 2022-11-15
Market Cap: $ 1,866,982
http://www.qualigeninc.com
Sec Filling | Patents | 5 employees

(US) Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA.

cancer lung cancer infectious disease lungs pancreatic treatment

add to watch list Paper trade email alert is off